Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Investigaciones Andina
versão impressa ISSN 0124-8146
Resumo
MACHADO ALBA, Jorge Enrique e VIDAL GUITART, Xavier. Response assessment and safety of different schemes of Anti-HIV Agents in Colombia. Investig. andina [online]. 2013, vol.15, n.27, pp.770-783. ISSN 0124-8146.
Introduction: estimate variables associated with treatment failure, treatment adherence, schema change and adverse reactions associated with the treatment of HIV/AIDS. Methods: cross-sectional study conducted in a population of patients with HIV/ AIDS antiretroviral treatment in 19 cities of Colombia affiliates at Social Security System in Health. We assessed socio-demographic variables, treatment regimens, and time from start of therapy and schema change, report non-adherence, treatment failure and adverse reactions. Were used bivariate and multivariate analysis. Results: we found 510 patients, antiretroviral therapy was modified to the first scheme in 56.4% of cases, nonadherence in 38.8%, treatment failure in 26.5% of patients, and the most common adverse reactions were: dyslipidemia (14.9%), gastric intolerance (9.2%) and anaemia (7.1%). The treatment regimen Lamivudine / Zidovudine + Efavirenz was associated with lower risk of schema change (p <0.001), treatment failure (p <0.001) and intolerance (p <0.001). Treatment failure was associated with a history of pneumocystosis, taking 7 pills a day, divided into 3-4 daily doses, in treatment for different comorbidities, lack of adherence and adverse effects associated with antiretrovirals. Conclusions: the identification of treatment regimens associated with poorer tolerability for their risk of affecting adherence to HIV management, with more tablets daily and consumed several times a day can guide the selection of drugs to ensure greater adherence and tolerability.
Palavras-chave : HIV Infections; Anti-HIV Agents; Pharmacovigilance; Drug Toxicity; Lamivudine; Zidovudine; Efavirenz.